Toggle navigation
Home
Search
Services
Blog
Contact
About
Computer-Assisted Non-Radioactive Multiplex Genotyping
Mao, Jen-I I.
Oscient Pharmaceuticals Corporation, Waltham, MA, United States
Search 27 grants from Jen-I Mao
Search grants from Oscient Pharmaceuticals Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Fred Hutchinson Cancer Research Center
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Identifying the sequences and factors that govern the fate of elongating RNAPII
Natural History of Familial Carcinoid Tumor
National Network of Libraries of Medicine (NNLM)
Smart and Connected Health (SCH) PI and Aspiring PI Meeting, 2015
on Cognitive Processes in Survey Responding
Recently added grants:
Mechanotransduction and YAP/TAZ Signaling in Pulmonary Arterial Hypertension
Lipid signaling in cardiac development and disease
Microbiome-based diagnosis of pneumonia in the acute respiratory distress syndrome
Circadian and sleep pathways to cardiometabolic disease risk: role of neurobehavioral processes
Smarter exosomes derived from engineered MSCs promote neo-vascularization
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44HG000295-03
Application #
2208690
Study Section
Special Emphasis Panel (ZRG7-SSS-2 (08))
Project Start
1991-02-01
Project End
1996-11-30
Budget Start
1994-12-01
Budget End
1996-11-30
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Institution
Name
Oscient Pharmaceuticals Corporation
Department
Type
DUNS #
City
Waltham
State
MA
Country
United States
Zip Code
02453
Related projects
NIH 1995
R44 HG
Computer-Assisted Non-Radioactive Multiplex Genotyping
Mao, Jen-I I. / Oscient Pharmaceuticals Corporation
NIH 1994
R44 HG
Computer-Assisted Non-Radioactive Multiplex Genotyping
Mao, Jen-I I. / Oscient Pharmaceuticals Corporation
Comments
Be the first to comment on this grant